www.courpharma.comHealthcare / BioTech & PharmaFounded: 2012
COUR Pharmaceuticals aims to advance novel therapies that reprogram the immune system for antigen-specific tolerance, focusing on the root of immune-mediated diseases. Their cutting-edge nanoparticle platform diverges from traditional symptom-suppressing treatments, offering a more targeted approach. Collaborating with Takeda on a leading celiac disease therapy, COUR has achieved the first instance of antigen-specific immune tolerance in autoimmune diseases. This breakthrough underscores the potential of their platform to address a wide array of immune and inflammatory conditions.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cour Pharmaceuticals Development.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.